Regeneron Pharmaceuticals, Inc. (REGN) is a biotechnologycompany headquartered in Tarrytown, New York. The company was founded in 1988. Originally focused onneurotrophic factors and their regenerative capabilities (thus the name), it branched out into the study of both cytokine and tyrosine kinase receptors.
Reported before open today (5/5/16) Earnings: EPS $2.57 Revenue $1.2B Estimates: EPS $2.58 Revenue $1.2B Up 5.06% in pre-market
Analyst Upgrade/Downgrade Update Brokerage firm: Chardan Capital Mkts Change: Coverage Reiterated/Price Target Changed Previous Rating: N/A Current Rating: Sell Previous Price Target: $325 Current Price Target: $300
REGN got a reprieve when Hillary got erased by Trump. But it's still having trouble getting over $435.
Regeneron reported a nearly 98 percent rise in quarterly profit on Thursday, partly helped by higher demand for its flagship eye treatment, Eylea. Net income rose to $387.7 million, or $3.34 per share, in the second quarter ended June 30, from $196.22 million, or $1.69 per share, a year earlier. Total revenue rose to $1.47 billion from $1.21 billion.
REGN looking real strong. Tested the 200 ma in October's selloff, and has been holding above it during the current selloff. Also been able to hold on to December's low. Real easy trade to place, with a stop if it closes below the 200 ma. If COVID ends up turning from pandemic into endemic...
